149.18MMarket Cap-2.69P/E (TTM)
1.950High1.780Low11.01KVolume1.950Open1.980Pre Close20.21KTurnover0.02%Turnover RatioLossP/E (Static)83.81MShares3.51152wk High15.61P/B103.44MFloat Cap1.29052wk Low--Dividend TTM58.11MShs Float11.950Historical High--Div YieldTTM8.59%Amplitude1.290Historical Low1.834Avg Price1Lot Size
Innate Pharma Stock Forum
Breakthrough ADC Drug Tackles Treatment-Resistant Cancers: New Clinical Data Revealed
Benzinga· 02:38
IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Nectin-4 expressi...
$Innate Pharma (IPHA.US)$ is doing well too
my swing for the day
it can be doubled
NFA
No comment yet